03-0208-00

SMC^® Human PD-L1 High Sensitivity Immunoassay Kit

kit sufficient for 96 wells

• Synonym(s): PD-L1 ultra-sensitive immunoassay, PD-L1 immunoassay kit, Programmed cell death protein ligand 1 kit, PD-L1 kit, Single Molecule Counting, SMC, SMC^®, PD-L1, Human PD-L1, Hu PD-L1, checkpoint protein PD-L1, Immuno-oncology PD-L1, PD-L1 Single Molecule Counting kit
• UNSPSC Code: 12161503
• NACRES: NA.51

Properties

• description: 100 μL of 1:4 Serum or 1:8 Plasma diluted in Standard Diluent
• Quality Level: 200
• species reactivity: human
• manufacturer/tradename: SMC^®
• assay range: intra-assay cv: ≤10%; (n=15); linearity: 85-110%; (Plasma); linearity: 91-129%; (Serum); recovery range: 108 -143%; (Serum); recovery range: 70-110%; (Plasma); sensitivity: 0.78 pg/mL; standard curve range: 0.39-400 pg/mL; inter-assay cv: ≤15%; (n=15)
• technique(s): single molecule counting: suitable
• input: serum; plasma (K2 EDTA)
• shipped in: wet ice
• storage temp.: 2-8°C

Description

General description

Programmed cell death protein ligand 1 (PD-L1), also known as cluster of differentiation 274 (CD274) and B7-H1, is a type 1 membrane protein of 290 amino acids. It is found in a variety of cell types and binds programmed cell death protein (PD-1). It has been indicated as playing a role in autoimmune disease, allograft responses, pregnancy, and other disease states. When PD-L1 binds to PD-1, an inhibitory signal is transmitted that ultimately reduces the proliferation of antigen-specific T cells and reduces the rate of apoptosis in regulatory T-cells. By doing so, PD-L1 contributes to the immune evasion of cancer tissues by suppressing the adaptive immune system. Blocking this activity is thought to restore anti-tumor activity. High PD-L1 expression is correlated with poor prognosis with some cancer types. High levels of the soluble form are also associated with poor prognosis and advanced tumor progression. Multiple PD-L1 inhibiting monoclonal antibodies have been approved as cancer therapeutics.

Research Category: Cancer

Research Sub-Category: Immuno-Oncology

Specificity

This assay was tested for cross-reactivity with PD-1. No cross-reactivity was detected with this analyte.

Application

Used for ultrasensitivite quantification of Human PD-L1 in human serum and plasma.

Features and Benefits

This SMC^® kit features:

• Accurate and reproducible performance on the state-of-the-art SMCxPRO^® ultrasensitive immunoassay system.
• Compatiblity with automated liquid handling

Legal Information

SMC is a registered trademark of Singulex

SMCxPRO is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Safety Information

• Pictograms: GHS08,GHS07
• Signal Word: Danger
• Hazard Statements: H302 + H312 + H332,H319,H360FD,H373,H412
• Precautionary Statements: P273 - P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Eye Irrit. 2 - Repr. 1B - STOT RE 2 Inhalation
• Target Organs: Respiratory Tract
• Storage Class Code: 6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects
• WGK: WGK 3
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable